Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed HER-2 positive breast cancer (immunohistochemistry 3+ or 2+ with FISH positivity).Diagnosis of advanced breast cancer in accordance with AJCC staging criteria.
Achieved complete response (CR) as evaluated by PET-CT or contrast-enhanced CT after receiving salvage therapy (within second-line) and maintained for 3 months.
Negative ctDNA-MRD (circulating tumor DNA - minimal residual disease) detection.
Negative CA153 detection.
ECOG performance status score of 0-2.
Expected survival ≥ 6 months.
The patient has signed an informed consent form, willing to cooperate with the study and accept regular follow-up.
You may not be if
Concomitant other malignant tumors (excluding breast cancer).
History of mental disorders or cognitive dysfunction, unable to cooperate with the study.
Pregnant or lactating women.
Severe cardiac, hepatic, or renal insufficiency.
Currently participating in other clinical trials that may affect the evaluation of this study's results.
Clareo Health | Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
